Authorization of tetrahydrocurcuminoids marketed by Sabinsa as novel food

Nutraveris

A successful application managed by Nutraveris.

The Commission implementing regulation (EU) 2022/961 of 20 June 2022 authorizes the use of tetrahydrocurcuminoids as novel food, known under the trademark Curcumin C3 Reduct®. This application prepared by Nutraveris, and submitted on behalf of Sabinsa Europe GmbH, has been submitted in January 2020.

This regulation authorizes the use of tetrahydrocurcuminoids in food supplements at a maximum level of 140 mg/day. Two labelling requirements are listed in the regulation, in order to avoid the consumption of the product by pregnant and lactating women, and by people consuming other curcumin and/or curcuminoids-containing products on the same day.

Tetrahydrocurcumonoids are the first curcuminoids authorized through a novel food procedure. The ingredient can be lawfully on the market on the 11 July 2022, with a protection of 5 year of this approval.

Commission implementing regulation (EU) 2022/961 of June 2022 authorizing the placing on the market of tetrahydrocurcuminoids as a novel food and amending implementing regulation (EU) 2017/2470.


Categories: nf
NOL Data Solution
NOL Compliance